Drug Approval | January 21, 2022
Bristol Myers Squibb receives approval for Abecma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
First launches expected in H1 2022
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The study will be published on the pre-print server, medRXiv, shortly
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Subscribe To Our Newsletter & Stay Updated
